Table 5 Ongoing trials using novel agents alone or in combination as front-line therapy for young MCL patients

Window

IR with With Hyper-CVAD Consolidation

Phase II, Open-Label

M.D. Anderson Cancer Center

NCT02427620

–

O-HyperCVAD/ O-MA

Phase II, Open Label

Roswell Park Cancer Institute

NCT01527149

Triangle

(1) R-CHOP /R-DHAP + ASCT

(2) R-CHOP+IBN/R-DHAP +ASCT +IBN maintenance ×2 ys

(3) R-CHOP+IBN/ R-DHAP + IBN maintenance × 2 ys

Phase III, Open-Label

Prof. Dr. M. Dreyling

NCT02858258

ECOG-ACRIN (EA4151)

patients with MRD (−) after induction:

(1)ASCT + R maintenance Open-Label

(2) R maintenance without ASCT

Randomized Phase III, Open-Label

ECOG-ACRIN Cancer Research Group

NCT03267433

BDH-MCL01

R-EDOCH/R-DHAP→HDT/ASCT or R-EDOCH/R-DHAP→MR or MTp

Phase III, Open-Label

Institute of Hematology & Blood Diseases Hospital

NCT02858804

–

IBN^a

Phase II, Open Label

M.D. Anderson Cancer Center

NCT03282396

–

BTZ

retrospective and prospective

Xian-Janssen Pharmaceutical Ltd.

NCT03053024

–

VCR

Phase II, Open-Label

University of Arizona

NCT00980395

–

BR/RAC

Phase I, Open-Label

Washington University School of Medicine

NCT 02728531

–

R-CHOP14 → R-HIDAC→RIT → HDT → ASCT

Phase I/II, Open-Label

Memorial Sloan Kettering Cancer Center

NCT 01484093